Xponance Inc. Raises Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Xponance Inc. raised its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 43.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,468 shares of the biotechnology company’s stock after buying an additional 5,597 shares during the quarter. Xponance Inc.’s holdings in ADMA Biologics were worth $206,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ADMA. LSV Asset Management bought a new position in shares of ADMA Biologics in the first quarter valued at $1,028,000. Seven Eight Capital LP bought a new position in shares of ADMA Biologics during the 2nd quarter worth about $1,992,000. BNP Paribas Financial Markets lifted its holdings in ADMA Biologics by 152.2% during the 1st quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after purchasing an additional 442,315 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in ADMA Biologics by 90.7% during the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after purchasing an additional 556,175 shares during the last quarter. Finally, Inspire Investing LLC raised its stake in shares of ADMA Biologics by 125.2% in the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock worth $1,249,000 after acquiring an additional 105,256 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ADMA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright lifted their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Mizuho lifted their price target on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $15.50.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $19.50 on Thursday. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $20.37. The stock has a market cap of $4.52 billion, a price-to-earnings ratio of -975.00 and a beta of 0.61. The company’s fifty day moving average is $16.75 and its 200 day moving average is $11.72.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the transaction, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. In the last 90 days, insiders sold 466,900 shares of company stock worth $8,224,121. Insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.